Renal Transplant Rejection

Nephrology
4
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
4
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Bristol Myers Squibb
NULOJIXApproved
belatacept
Bristol Myers Squibb
Selective T Cell Costimulation Blocker [EPC]injection2011

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
BelataceptPhase 41 trial
Active Trials
NCT01953120Completed20Est. Apr 2021
Novartis
NovartisBASEL, Switzerland
1 program
1
SimulectPhase 41 trial
Active Trials
NCT02377193Completed60Est. Jan 2017
Veloxis Pharmaceuticals
1 program
1
Tacrolimus Extended Release Oral TabletPhase 41 trial
Active Trials
NCT03511560CompletedEst. Jul 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet
Bristol Myers SquibbBelatacept
NovartisSimulect

Clinical Trials (3)

Total enrollment: 80 patients across 3 trials

NCT03511560Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Start: Jul 2018Est. completion: Jul 2021
Phase 4Completed
NCT01953120Bristol Myers SquibbBelatacept

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

Start: Oct 2013Est. completion: Apr 202120 patients
Phase 4Completed
NCT02377193NovartisSimulect

Simulect Versus ATG in Sensitized Renal Transplant Patient

Start: Sep 2013Est. completion: Jan 201760 patients
Phase 4Completed

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
1w ago

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Specialty Account Manager, Nephrology- South Houston, Texas

Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)